Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel Free TMCI Stock Alerts

Treace Medical Concepts (TMCI) Competitors

Treace Medical Concepts logo
$1.88 +0.05 (+2.73%)
Closing price 04:00 PM Eastern
Extended Trading
$1.88 0.00 (0.00%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

TMCI vs. MDXG, BBNX, KIDS, DCTH, and CLPT

Should you be buying Treace Medical Concepts stock or one of its competitors? The main competitors of Treace Medical Concepts include MiMedx Group (MDXG), Beta Bionics (BBNX), OrthoPediatrics (KIDS), Delcath Systems (DCTH), and ClearPoint Neuro (CLPT). These companies are all part of the "medical equipment" industry.

How does Treace Medical Concepts compare to MiMedx Group?

Treace Medical Concepts (NASDAQ:TMCI) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

MiMedx Group has higher revenue and earnings than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Treace Medical Concepts$212.69M0.57-$59M-$0.94N/A
MiMedx Group$389.42M1.39$48.58M$0.2018.20

In the previous week, MiMedx Group had 14 more articles in the media than Treace Medical Concepts. MarketBeat recorded 19 mentions for MiMedx Group and 5 mentions for Treace Medical Concepts. Treace Medical Concepts' average media sentiment score of 0.27 beat MiMedx Group's score of 0.15 indicating that Treace Medical Concepts is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Treace Medical Concepts
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
MiMedx Group
1 Very Positive mention(s)
4 Positive mention(s)
7 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral

Treace Medical Concepts has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500.

Treace Medical Concepts currently has a consensus price target of $4.77, suggesting a potential upside of 153.72%. MiMedx Group has a consensus price target of $8.50, suggesting a potential upside of 133.52%. Given Treace Medical Concepts' higher probable upside, equities research analysts plainly believe Treace Medical Concepts is more favorable than MiMedx Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Treace Medical Concepts
2 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.86
MiMedx Group
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71

84.1% of Treace Medical Concepts shares are held by institutional investors. Comparatively, 79.2% of MiMedx Group shares are held by institutional investors. 23.4% of Treace Medical Concepts shares are held by insiders. Comparatively, 1.7% of MiMedx Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

MiMedx Group has a net margin of 7.88% compared to Treace Medical Concepts' net margin of -27.74%. MiMedx Group's return on equity of 21.03% beat Treace Medical Concepts' return on equity.

Company Net Margins Return on Equity Return on Assets
Treace Medical Concepts-27.74% -59.91% -28.44%
MiMedx Group 7.88%21.03%15.92%

Summary

MiMedx Group beats Treace Medical Concepts on 12 of the 16 factors compared between the two stocks.

How does Treace Medical Concepts compare to Beta Bionics?

Treace Medical Concepts (NASDAQ:TMCI) and Beta Bionics (NASDAQ:BBNX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

Treace Medical Concepts has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Treace Medical Concepts, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Treace Medical Concepts$212.69M0.57-$59M-$0.94N/A
Beta Bionics$110.24M4.05-$73.20M-$1.51N/A

In the previous week, Treace Medical Concepts had 3 more articles in the media than Beta Bionics. MarketBeat recorded 5 mentions for Treace Medical Concepts and 2 mentions for Beta Bionics. Treace Medical Concepts' average media sentiment score of 0.27 beat Beta Bionics' score of 0.00 indicating that Treace Medical Concepts is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Treace Medical Concepts
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Beta Bionics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Treace Medical Concepts has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, Beta Bionics has a beta of 3.29, indicating that its stock price is 229% more volatile than the S&P 500.

Treace Medical Concepts currently has a consensus price target of $4.77, indicating a potential upside of 153.72%. Beta Bionics has a consensus price target of $22.00, indicating a potential upside of 119.78%. Given Treace Medical Concepts' higher probable upside, equities research analysts clearly believe Treace Medical Concepts is more favorable than Beta Bionics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Treace Medical Concepts
2 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.86
Beta Bionics
1 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.67

84.1% of Treace Medical Concepts shares are owned by institutional investors. 23.4% of Treace Medical Concepts shares are owned by insiders. Comparatively, 5.3% of Beta Bionics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Treace Medical Concepts has a net margin of -27.74% compared to Beta Bionics' net margin of -60.27%. Beta Bionics' return on equity of -23.00% beat Treace Medical Concepts' return on equity.

Company Net Margins Return on Equity Return on Assets
Treace Medical Concepts-27.74% -59.91% -28.44%
Beta Bionics -60.27%-23.00%-20.55%

Summary

Treace Medical Concepts beats Beta Bionics on 10 of the 17 factors compared between the two stocks.

How does Treace Medical Concepts compare to OrthoPediatrics?

Treace Medical Concepts (NASDAQ:TMCI) and OrthoPediatrics (NASDAQ:KIDS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

In the previous week, OrthoPediatrics had 8 more articles in the media than Treace Medical Concepts. MarketBeat recorded 13 mentions for OrthoPediatrics and 5 mentions for Treace Medical Concepts. OrthoPediatrics' average media sentiment score of 0.49 beat Treace Medical Concepts' score of 0.27 indicating that OrthoPediatrics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Treace Medical Concepts
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
OrthoPediatrics
3 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

84.1% of Treace Medical Concepts shares are owned by institutional investors. Comparatively, 69.1% of OrthoPediatrics shares are owned by institutional investors. 23.4% of Treace Medical Concepts shares are owned by company insiders. Comparatively, 32.7% of OrthoPediatrics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Treace Medical Concepts has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, OrthoPediatrics has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500.

Treace Medical Concepts presently has a consensus price target of $4.77, indicating a potential upside of 153.72%. OrthoPediatrics has a consensus price target of $24.44, indicating a potential upside of 43.45%. Given Treace Medical Concepts' higher possible upside, research analysts clearly believe Treace Medical Concepts is more favorable than OrthoPediatrics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Treace Medical Concepts
2 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.86
OrthoPediatrics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82

OrthoPediatrics has higher revenue and earnings than Treace Medical Concepts. OrthoPediatrics is trading at a lower price-to-earnings ratio than Treace Medical Concepts, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Treace Medical Concepts$212.69M0.57-$59M-$0.94N/A
OrthoPediatrics$243.30M1.80-$39.65M-$1.68N/A

OrthoPediatrics has a net margin of -16.31% compared to Treace Medical Concepts' net margin of -27.74%. OrthoPediatrics' return on equity of -6.95% beat Treace Medical Concepts' return on equity.

Company Net Margins Return on Equity Return on Assets
Treace Medical Concepts-27.74% -59.91% -28.44%
OrthoPediatrics -16.31%-6.95%-4.86%

Summary

OrthoPediatrics beats Treace Medical Concepts on 12 of the 17 factors compared between the two stocks.

How does Treace Medical Concepts compare to Delcath Systems?

Delcath Systems (NASDAQ:DCTH) and Treace Medical Concepts (NASDAQ:TMCI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

In the previous week, Treace Medical Concepts had 3 more articles in the media than Delcath Systems. MarketBeat recorded 5 mentions for Treace Medical Concepts and 2 mentions for Delcath Systems. Treace Medical Concepts' average media sentiment score of 0.27 beat Delcath Systems' score of 0.00 indicating that Treace Medical Concepts is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Delcath Systems
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Treace Medical Concepts
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

61.1% of Delcath Systems shares are held by institutional investors. Comparatively, 84.1% of Treace Medical Concepts shares are held by institutional investors. 19.4% of Delcath Systems shares are held by company insiders. Comparatively, 23.4% of Treace Medical Concepts shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Delcath Systems has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, Treace Medical Concepts has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500.

Delcath Systems presently has a consensus price target of $22.50, suggesting a potential upside of 95.14%. Treace Medical Concepts has a consensus price target of $4.77, suggesting a potential upside of 153.72%. Given Treace Medical Concepts' higher possible upside, analysts clearly believe Treace Medical Concepts is more favorable than Delcath Systems.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Delcath Systems
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
Treace Medical Concepts
2 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.86

Delcath Systems has higher earnings, but lower revenue than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Delcath Systems$85.23M4.66$2.70M$0.07164.71
Treace Medical Concepts$212.69M0.57-$59M-$0.94N/A

Delcath Systems has a net margin of 3.17% compared to Treace Medical Concepts' net margin of -27.74%. Delcath Systems' return on equity of 2.63% beat Treace Medical Concepts' return on equity.

Company Net Margins Return on Equity Return on Assets
Delcath Systems3.17% 2.63% 2.39%
Treace Medical Concepts -27.74%-59.91%-28.44%

Summary

Delcath Systems beats Treace Medical Concepts on 9 of the 16 factors compared between the two stocks.

How does Treace Medical Concepts compare to ClearPoint Neuro?

Treace Medical Concepts (NASDAQ:TMCI) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

ClearPoint Neuro has lower revenue, but higher earnings than Treace Medical Concepts. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Treace Medical Concepts, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Treace Medical Concepts$212.69M0.57-$59M-$0.94N/A
ClearPoint Neuro$36.97M9.00-$25.54M-$0.91N/A

84.1% of Treace Medical Concepts shares are held by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are held by institutional investors. 23.4% of Treace Medical Concepts shares are held by insiders. Comparatively, 6.9% of ClearPoint Neuro shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Treace Medical Concepts has a net margin of -27.74% compared to ClearPoint Neuro's net margin of -69.08%. Treace Medical Concepts' return on equity of -59.91% beat ClearPoint Neuro's return on equity.

Company Net Margins Return on Equity Return on Assets
Treace Medical Concepts-27.74% -59.91% -28.44%
ClearPoint Neuro -69.08%-122.17%-40.69%

Treace Medical Concepts has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, ClearPoint Neuro has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500.

In the previous week, Treace Medical Concepts had 4 more articles in the media than ClearPoint Neuro. MarketBeat recorded 5 mentions for Treace Medical Concepts and 1 mentions for ClearPoint Neuro. ClearPoint Neuro's average media sentiment score of 0.36 beat Treace Medical Concepts' score of 0.27 indicating that ClearPoint Neuro is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Treace Medical Concepts
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
ClearPoint Neuro
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Treace Medical Concepts currently has a consensus target price of $4.77, suggesting a potential upside of 153.72%. ClearPoint Neuro has a consensus target price of $14.50, suggesting a potential upside of 30.63%. Given Treace Medical Concepts' higher probable upside, research analysts clearly believe Treace Medical Concepts is more favorable than ClearPoint Neuro.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Treace Medical Concepts
2 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.86
ClearPoint Neuro
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Summary

Treace Medical Concepts beats ClearPoint Neuro on 9 of the 16 factors compared between the two stocks.

Get Treace Medical Concepts News Delivered to You Automatically

Sign up to receive the latest news and ratings for TMCI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TMCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TMCI vs. The Competition

Export
MetricTreace Medical ConceptsMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market Cap$121.79M$7.14B$6.25B$11.87B
Dividend YieldN/A1.75%2.73%5.21%
P/E Ratio-2.0029.6029.0428.47
Price / Sales0.5755.86476.6160.94
Price / CashN/A24.9127.6236.52
Price / Book1.377.189.676.67
Net Income-$59M$158.34M$3.55B$332.53M
7 Day Performance-1.57%2.64%1.70%2.01%
1 Month Performance29.66%4.99%5.62%9.20%
1 Year Performance-74.32%-3.14%34.42%39.59%

Treace Medical Concepts Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TMCI
Treace Medical Concepts
1.6309 of 5 stars		$1.88
+2.7%		$4.77
+153.7%		N/A$121.79M$212.69MN/A250
MDXG
MiMedx Group
4.3569 of 5 stars		$3.40
+1.8%		$8.67
+154.9%		N/A$496.21M$418.63M7.42870
BBNX
Beta Bionics
2.7444 of 5 stars		$10.08
-5.4%		$22.00
+118.3%		N/A$474.58M$100.25MN/A294
KIDS
OrthoPediatrics
3.1656 of 5 stars		$15.14
-4.3%		$24.78
+63.7%		N/A$406.36M$236.35MN/A200
DCTH
Delcath Systems
1.6174 of 5 stars		$10.55
-2.7%		$22.50
+113.3%		N/A$373.49M$85.23M154.8660

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TMCI) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel